Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update

About this update from Zelluna Asa

[{"type":"image","alt":"Zelluna ASA","displaySize":"","headline":null,"caption":"Zelluna ASA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C3Qdgv86SfCXtr_6x5fSRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69","width":300,"height":106}},"lazy":false},{"type":"text","content":"Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its second quarter 2025 results today.","length":238,"tagName":"p"},{"type":"text","content":"Webcast scheduled for 20 August 2025, at 09:00 (CET). Link to webcast here.","length":75,"tagName":"p"},{"type":"text","content":"Second Quarter 2025 Business Update","length":35,"tagName":"p"},{"type":"text","content":"Highlights","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"On track toward IND/CTA submission in 2H 2025 and first-in-human trial initiation in 1H 2026.","length":93,"tagName":"p"}]},{"val":[{"type":"text","content":"Broadened regulatory engagement: following positive FDA pre-IND feedback (Q2 2024), submitted a scientific advice briefing package to the UK MHRA in July 2025 for ZI-MA4-1.","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"Initiated GMP manufacturing of clinical material in July 2025, a major step in clinical readiness; scalable platform developed with Catalent can deliver hundreds of doses from a single batch.","length":191,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong support from leading clinical experts and sites; refined trial design and moving to operational readiness ahead of IND/CTA submission","length":140,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":596,"olType":false},{"type":"text","content":"Financial highlights","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total operating expenses amounted to MNOK 38.4 in Q2 2025, and MNOK 67.8 YTD. Total loss was MNOK 37.5 for the period and MNOK 66.0 YTD.","length":136,"tagName":"p"}]},{"val":[{"type":"text","content":"Net negative cash fl...

More updates from Zelluna Asa